TocopheRx is focused on developing innovative medicines that reduce the stress of infertility treatments for couples desiring to achieve the family plans. Our disruptive technology is a small molecule that combines the activity of both hormones used to treat infertility into a single molecule that will be delivered in a tablet to treat the infertile partner in a couple, whether it is the woman or the man.
The most significant trend affecting the fertility of both women and men is postponement of child-bearing until careers have been established. Whether your decision relies on banking oocytes for the right partner, freezing embryos for future implantation, or treatment now to address current fertility problems, an orally active treatment regimen can be less stressful for both partners.
From the inception of TocopheRx, we have been committed to develop fertility treatments that are extremely safe and highly effective. Our development program has a strong emphasis on both efficacy and safety for patients receiving the treatment. Our goal is to help you reach your family objectives with less stress due to drug administration and earlier access to superior treatment options than can be achieved currently.
Former Head of Fertility research and early development at EMD Serono. 20 years experience in early drug development in Reproductive Health: J&J: antiprogestins & gonadotropin antagonists; EMDS: JNK inhibitors; gonadotropin analogs; cytokine gonadotropin fusion proteins; GPCR agonists.
Weizmann Institute Postdoc fellow. 10+ years experience in pharmacology. Selva joined the Serono Reproductive Biology Institute and was instrumental in the development of long acting FSH, innovations for uterine diseases, endometriosis and PCOS.
Scrips Research Institute Postdoc fellow. Experienced medicinal chemist leader in oncology, CNS, Fertility and Immunology. Expertise: small molecule, macrocycle, and antibody-drug conjugate drug discovery. FSHR chemistry leader from Hit, Lead, to preclinical candidates.
VP and Managing Director of MS Ventures. Started MS Ventures in 2009. Formerly Director in Biotech Investment Banking at Fortis. Board Director at AmbrX, Padlock Therapeutics, F-Star and others.
Senior Investment Director MS Ventures. Formerly at Aescap and Atlas Ventures. Board Director at Raze Therapeutics, Progyny, Asceneuron, Forendo and others.
Associate, MS Ventures. Formerly scout and transactor with increasing managerial responsibilities for global BD and Licensing at Merck Serono, closed multiple transactions. Board Observer for TocopheRx and others.
Dr. Alper co-founded Boston IVF in 1986. Dr. Alper is an Associate Clinical Professor at Harvard Medical School. His interest of in vitro fertilization has led him to be involved in many research studies sponsored by the National Institutes of Health (NIH). His focus of research has been to maintain the highest quality of treatment in IVF and in other areas of clinical and scientific research such as egg freezing and fertility diagnostics.
Professor Macklon trained at the University of Edinburgh. Former Chair of Infertility and periconceptional Medicine at the University Medical Center Utrecht, NL and led largest IVF unit in the NL. Macklon founded the Dutch Society for Reproductive Medicine. Member of the ESHRE Advisory Board. Research interest in ovarian stimulation, implantation and periconceptional deterimants. > 100 peer reviewed articles.
Dr. Bosch is a former obstetrics and gynecology specialist at the Hospital La Fe in Valencia and an author of peer-reviewed journal articles on the myriad topics surrounding infertility and assisted reproductive technologies. Member of ASRM Advisory Board
Dr. Zitzman trained at the University of Munster, Arkansas and Columbia. He is a specialist in internal medicine, endocrinology and andrology. Zitzmann is largely involved in the research of the interplay of genetic issues, hormones, psychological characteristics and obesity. Zitzman has received several international awards and grants in recognition of his work and is a member of international committees as well as journal editorial boards.